Why MaxCyte, Inc.’s (MXCT) Stock Is Up 5.12%
As of Wednesday, August 19, MaxCyte, Inc.’s MXCT share price has surged by 5.12%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Commentary & Analysis
Why MaxCyte, Inc.’s (MXCT) Stock Is Down 5.40%
As of Friday, August 14, MaxCyte, Inc.’s MXCT share price has dipped by 5.40%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why MaxCyte, Inc.’s (MXCT) Stock Is Up 11.81%
As of Thursday, August 13, MaxCyte, Inc.’s MXCT share price has surged by 11.81%, which has investors questioning if this is right time to sell.Michael Rose
Why MaxCyte, Inc.’s (MXCT) Stock Is Up 18.90%
As of Thursday, August 13, MaxCyte, Inc.’s MXCT share price has surged by 18.90%, which has investors questioning if this is right time to sell.Tudor Pop
Why MaxCyte, Inc.’s (MXCT) Stock Is Up 5.13%
As of Tuesday, July 21, MaxCyte, Inc.’s MXCT share price has surged by 5.13%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | MXCT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $142.9 | $3,076.5 | 24% |
|
| Shares Out (Mil) | 106.8 | 96.5 | 63% |
|
| Institutional Ownership | 97.5% | 90.0% | 74% |
|
| Float (Mil) | 93.7 | 71.5 | 60% |
|
| Beta | 1.49 | 1.22 | 83% |
|
| Avg Daily Volume (000s) | 1,160 | 710 | 73% |
|
| Price Change (52-week) |
(1.1%) | 89.4% | 44% |
|
| Growth | MXCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 4.7% | 7.8% | 35% |
|
| Net Income (5yr) | (30.5%) | (13.7%) | 13% |
|
| EPS (5yr) | (19.8%) | 0.7% | 13 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (27.7%) | (15.0%) | 22% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 4 | 4 | |
| Current EPS | ($0.083) | ($0.273) | ($0.238) | |
| Month Ago EPS | ($0.077) | ($0.276) | ($0.234) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.077) | ($0.275) | ($0.249) | |
| Year/Year Chg | 0.0% | (34.8%) | (42.5%) | |
| Financials | MXCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $31 | $800 | 16% |
|
| Net Income (TTM) (Mil) | ($36) | ($31) | 19% |
|
| EPS (TTM) | ($0.334) | ($0.300) | 30% |
|
| Operating Cash Flow (TTM) (Mil) | ($23) | $47 | 14% |
|
| Net Cash Flow (TTM) (Mil) | $-0 | $5 | 42% |
|
| Long-Term Debt (Q1) (Mil) | $16 | $270 | 31% |
|
| Enterprise Value (Q1) (Mil) | $48 | $3,795 | 16% |
|
| Valuation | MXCT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.92 | 3.68 | 19% |
|
| P/E | na | 39.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.5 | na |
|
| Ratios | MXCT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 79.2% | 47.7% | 88% |
|
| Net Margin | (114.8%) | (3.2%) | 7% |
|
| ROA | (17.6%) | (4.3%) | 21% |
|
| ROE | (20.4%) | (7.9%) | 23% |
|
| Liabilities to Assets | 14.0% | 42.0% | 9% |
|
| F-Score | 3 | 5 | 18% |
|
MaxCyte, Inc. did not pass any screens on 8/20/2026.
